DEA Unveils Rules for Telehealth Prescribing of Adderall, Suboxone

After 16 years, the DEA has announced plans for a special registration process allowing telemedicine providers to prescribe controlled substances like opioids and ADHD medications. While this move fulfills a long-overdue mandate, the proposal comes with restrictions that have sparked pushback from telehealth providers. For many, this raises concerns about access to care, especially for patients in rural areas or those who rely on virtual appointments. It’s a big step, but with the policy still awaiting final approval, its future remains uncertain.

 DEA unveils Telehealth rules for Adderall, Buprenorphine, other controlled medications

How Digital Health VC Funding Evolved in 2024

In 2024, US digital health startups raised $10.1 billion, with a focus on early-stage funding and areas like AI and disease treatment. Major VC firms like a16z and General Catalyst are gaining influence, while funding is increasingly concentrated among a few large players. Startups must adapt to this changing landscape to succeed.